Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 6, 2004, Pages 386-394

  Van Besien, Koen ^a   Mehra, Rakesh ^b   Wadehra, Navin ^a   Stock, Wendy ^a   Khouri, Issa ^b   Giralt, Sergio ^b   Devine, Steve ^a   Wickrema, Amittha ^a   Peace, David ^a   Sosman, Jeff ^a   Gajewski, Jim ^a   Champlin, Richard ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Interleukin 2; Non Hodgkin lymphoma; Peripheral blood stem cells; Survival

Indexed keywords

ACICLOVIR; ANTIEMETIC AGENT; ANTIPYRETIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 2; MELPHALAN; MESNA; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURE MEDIUM; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG TOXICITY; FEVER; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL TOXICITY; GRAM NEGATIVE SEPSIS; HEADACHE; HUMAN; HYPOTENSION; HYPOXIA; IN VITRO STUDY; LETHARGY; LIVER TOXICITY; LUNG EMBOLISM; LUNG TOXICITY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PATIENT ATTITUDE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; SALVAGE THERAPY; SKIN NECROSIS; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CULTURE TECHNIQUES; ETOPOSIDE; HUMANS; IFOSFAMIDE; INTERLEUKIN-2; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 2442585167     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.01.004     Document Type: Article

References (60)

1. Philip T. Guglielmi C. Hagenbeek A. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 1995 1540-1545
2. van Besien K. Rodriguez A. Tomany S. et al. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival Bone Marrow Transplant 27 2001 397-404
3. Smith S.M. Grinblatt D. van Besien K. Autologous and allogeneic transplantation for aggressive NHL Cytotherapy 4 2002 223-240
4. Smalley R.V. Andersen J.W. Hawkins M.J. et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma N Engl J Med 327 1992 1336-1341
5. Smalley R.V. Weller E. Hawkins M. et al. Alpha interferon in non-Hodgkin's lymphoma-an update of the ECOG I-COPA trial Blood 92 1998 2004 [abstract]
6. Andersen J.W. Smalley R.V. Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up N Engl J Med 329 1993 1821-1822
7. Weber J.S. Yang J.C. Topalian S.L. et al. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma J Clin Oncol 10 1992 33-40
8. Gisselbrecht C. Maraninchi D. Pico J.-L. et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study Blood 83 1994 2081-2085
9. Gottlieb D.J. Brenner M.K. Heslop H.E. et al. A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease Br J Cancer 60 1989 610-615
10. Verma U.N. Charak B.S. Rajagopal C. Mazumder A. Interleukin-2 in bone marrow transplantation Cancer Treat Res 76 1995 315-336 [review]
11. Margolin K. van Besien K. Wright C. et al. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma Biol Blood Marrow Transplant 5 1999 36-45
12. Dixon D.O. Simon R. Sample size considerations for studies comparing survival curves using historical controls J Clin Epidemiol 41 1988 1209-1213
13. Kaplan E.L. Meier P. Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457-481
14. Altman D.G. Analysis of Survival Times. Practical Statistics for Medical Research 1991 Chapman - HallLondon 365-395
15. Shimoni A. Korbling M. Champlin R. Molldrem J. Cryofibrinogenemia and skin necrosis in a patient with diffuse large cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation Bone Marrow Transplant 26 2000 1343-1345
16. Van Besien K.W. Tabocoff J. Rodriguez M.A. et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity Bone Marrow Transplant 15 1995 549-555
17. Philip T. Armitage J.O. Spitzer G. et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high-grade-non-Hodgkin's lymphoma N Engl J Med 316 1987 1493-1498
18. Rosenberg S.A. The immunotherapy and gene therapy of cancer J Clin Oncol 10 1992 180-199
19. Maraninchi D. Blaise D. Viens P. et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse Blood 78 1991 2182-2187
20. Foa R. Meloni G. Tosti S. et al. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study Br J Haematol 77 1991 491-496
21. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation Bone Marrow Transplant 5 1990 209-226
22. Lum L.G. The kinetics of immune reconstitution after human marrow transplantation Blood 69 1987 369-380
23. Reittie J.E. Gottlieb D. Heslop H.E. et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy Blood 73 1989 1351-1358
24. + natural killer cells after bone marrow transplantation Blood 79 1992 3239-3244
25. Porrata L.F. Inwards D.J. Lacy M.Q. Markovic S.N. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation Bone Marrow Transplant 28 2001 673-680
26. Siegel J.P. Puri R.K. Interleukin-2 toxicity J Clin Oncol 9 1991 694-704
27. Weisdorf D.J. Anderson P.M. Blazar B.R. et al. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia - a phase I study Transplantation 55 1993 61-66
28. Blaise D. Olive D. Stoppa A.M. et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation Blood 76 1990 1092-1097
29. Negrier S. Ranchere J.Y. Philip I. et al. Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study Bone Marrow Transplant 8 1991 259-264
30. Barlogie B. Velasquez W.S. Alexanian R. Cabanillas F. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma J Clin Oncol 7 1989 1514-1517
31. Soiffer R.J. Murray C. Cochran K. et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell- depleted allogeneic bone marrow transplantation Blood 79 1992 517-526
32. Soiffer R.J. Murray C. Gonin R. Ritz J. Effect of low dose interleukin-2 on disease relapse after T-cell depleted allogeneic transplantation Blood 84 1994 964-971
33. Robinson N. Benyunes M.C. Thompson J.A. et al. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study Bone Marrow Transplant 19 1997 435-442
34. Robinson N. Sanders J.E. Benyunes M.C. et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia Blood 87 1996 1249-1254
35. Baumgarten E. Schmid H. Pohl U. et al. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia Leukemia 8 1994 850-855
36. Vlk V. Eckschlager T. Kavan P. et al. Clinical ineffectiveness of IL-2 and/or IFN alpha administration after autologous PBSC transplantation in pediatric oncological patients Pediatr Hematol Oncol 17 2000 31-44
37. Burns L.J. Weisdorf D.J. DeFor T.E. et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial Bone Marrow Transplant 32 2003 177-186
38. Nagler A. Ackerstein A. Or R. Naparstek E. Slavin S. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation Blood 89 1997 3951-3959
39. Solal-Celigny P. Lepage E. Brousse N. et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des lymphomes Folliculaires 86 Trial J Clin Oncol 16 1998 2332-2338
40. Blaise D. Attal M. Reiffers J. et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission Eur Cytokine Netw 11 2000 91-98
41. - bone marrow progenitors J Immunol 150 1993 5263-5269
42. - primitive progenitors in long-term bone marrow culture Blood 80 1992 2182-2187
43. Silva M.R. Ascensao J.L. Generation of human natural killer cells from pharmacologically purged bone marrow Br J Haematol 89 1995 34-40
44. Van den Brink M.R.M. Voogt P.J. Marijt W.A.F. et al. Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro Blood 74 1989 354-360
45. Long G.S. Cramer D.V. Harnaha J.B. Hiserodt J.C. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms Bone Marrow Transplant 6 1990 169-177
46. Gambacorti-Passerini C. Rivoltini L. Fizzotti M. et al. Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells Br J Haematol 78 1996 197-205
47. Hajek R. Koristek Z. Vinklarkova J. et al. Interleukin-2 activation of haematopoietic stem cells Acta Med Austriaca 29 2002 61-67
48. Beaujean F. Bernaudin F. Kuentz M. et al. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia Bone Marrow Transplant 15 1995 691-696
49. Charak B.S. Brynes R.K. Chogyoji M. Mazumder A. Lymphokine-activated killer cells in autologous bone marrow transplantation: evidence against inhibition of engraftment in vivo Transplant 54 1992 1008-1013
50. Klingemann H.-G. Deal H. Reid D. Eaves C.J. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts Exp Hematol 21 1993 1263-1270
51. Klingemann H.G. Eaves C.J. Barnett M.J. et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration Bone Marrow Transplant 14 1994 389-396
52. Charak B.S. Brynes R.K. Groshen S. Chen S.-C. Mazumder A. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice Blood 76 1990 2187-2190
53. Charak B.S. Choudhary G.D. Tefft M. Mazumder A. Interleukin-2 in bone marrow transplantation: preclinical studies Bone Marrow Transplant 10 1992 103-111
54. Charak B.S. Areman E.M. Dickerson S.A. et al. A novel approach to immunomodulation of frozen human bone marrow with interleukin-2 for clinical application Bone Marrow Transplant 11 1993 147-154
55. Margolin K.A. Wright C. Forman S.J. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells Leukemia 11 1997 723-728
56. van Besien K. Margolin K. Champlin R. Forman S. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells Cancer J Sci Am 3suppl 1 1997 S54-S58
57. Caligiuri M.A. Murray C. Robertson M.J. et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2 J Clin Invest 91 1993 123-132
58. Sosman J.A. Mier J.W. Biological drug duo delivers one-two tumor punch Nat Med 9 2003 649-650
59. Samlowski W.E. Petersen R. Cuzzocrea S. et al. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects Nat Med 9 2003 750-755
60. Hursh D.A. Gluck A. Yuen A. et al. IL-2 plus rituximab results in clinical responses in advanced patients with non-Hodgkin's lymphoma related to the degree of NK expansion Proc Am Soc Clin Oncol 15 2002 1131 [abstract]